Thu Dec 6, 2012 9:36am EST
(Reuters) – Trimel Pharmaceuticals Corp pronounced a initial drug to provide hypogonadism, or low testosterone levels, in group met a categorical idea of a late-stage study.
The association pronounced patients who were administered a intranasal drug CompleoTRT for 90 days showed normal testosterone levels within a U.S. Food and Drug Administration’s efficiency superintendence for a testosterone deputy therapy.
It combined that no drug-related critical inauspicious events were observed.
Trimel, that took over a growth of a drug in May 2009, pronounced it is collecting additional nasal reserve information from patients administered a drug for adult to 360 days as partial of a selling focus to a FDA.
The Ontario-based association expects to accumulate a information by a initial entertain of 2013.
Shares of Trimel, that has a marketplace value of about C$177 million, sealed during C$1.95 on a Toronto Stock Exchange on Wednesday.
(Reporting by Krithika Krishnamurthy in Bangalore; Editing by Roshni Menon)
More on: Health Medicine Network